2025-02-25 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Review

**0. Key Figures:**

* **Cumulative Return (VRTX):** 172.33%
* **Cumulative Return (VOO):** 117.28%
* **Return Difference:** 55.0%
* **Relative Divergence:** 75.8% (Indicates VRTX significantly outperformed VOO historically, relative to its historical range of outperformance)
* **Current Price:** $481.65
* **Expected Return (2+ years):** 15.7% above S&P 500

**1. Company Overview and Performance Comparison:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.  VRTX has significantly outperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return exceeding VOO's by 55 percentage points.  The relative divergence of 75.8% indicates this outperformance is relatively high compared to its historical range.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.5 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.5 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.2 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.7 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.4 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.2 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.5 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.4 |
| 2023-2025  | 64.0% | 13.7% | 6.0% | 0.5 | 123.7 |

The table shows high CAGR (Compound Annual Growth Rate) figures across most periods, indicating strong historical performance. However, the significant negative alpha in 2019-2021 and the varying betas suggest volatility and periods of underperformance relative to the market.


**2. Recent Price Movement:**

* **Closing Price:** $481.65
* **5-day Moving Average:** $476.02
* **20-day Moving Average:** $464.89
* **60-day Moving Average:** $444.83

The price is above all three moving averages, suggesting a positive short-term trend.  The recent close shows a slight decrease compared to the previous close (-0.53%).


**3. Technical Indicators and Expected Return:**

* **RSI:** 55.91 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.205 (Positive, indicating bullish momentum)
* **Delta_Previous_Relative_Divergence:** 10.9 (+), suggesting short-term upward momentum.
* **Expected Return (2+ years):** 15.7% above S&P 500. This indicates a significant potential for outperformance in the long term.  The recent price drop is relatively minor and doesn't suggest a significant market shift.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-11-05 | 4.05   | $2.77 B        |
| 2024-08-02 | -13.92 | $2.65 B        |
| 2024-05-07 | 4.26   | $2.69 B        |
| 2023-11-07 | 4.01   | $2.48 B        |
| 2024-11-05 | 4.01   | $2.48 B        |

The earnings data shows significant volatility. The large negative EPS in August 2024 requires further investigation to understand the underlying causes.  Otherwise, EPS is generally positive and revenue shows a consistent upward trend.  Note the duplicate entry for 2024-11-05 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.91B | 85.46%       |
| 2024-09-30 | $2.77B | 85.84%       |
| 2024-06-30 | $2.65B | 85.94%       |
| 2024-03-31 | $2.69B | 87.27%       |
| 2023-12-31 | $2.52B | 85.38%       |

Revenue shows consistent growth, and profit margins remain high and stable.


**Capital and Profitability:**

| Quarter | Equity   | ROE         |
|---------|----------|-------------|
| 2024-12-31 | $16.41B  | 5.56%       |
| 2024-09-30 | $15.63B  | 6.69%       |
| 2024-06-30 | $14.77B  | -24.32%      |
| 2024-03-31 | $18.55B  | 5.93%       |
| 2023-12-31 | $17.58B  | 5.51%       |

Equity shows some fluctuation, and ROE experienced a significant negative value in Q2 2024. This warrants further investigation.

**6. Overall Analysis:**

VRTX has demonstrated strong historical performance significantly outpacing the S&P 500.  Technical indicators suggest positive short-term momentum, and the long-term expected return is considerably high.  However, recent earnings show volatility, particularly the substantial negative EPS in Q2 2024 and fluctuations in equity and ROE.  Further investigation into the causes of these fluctuations (e.g., one-time expenses, changes in accounting methods) is necessary before drawing definitive conclusions.  While the long-term outlook appears positive, potential investors should carefully analyze the recent earnings volatility before making investment decisions.
